Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
October 14 2021 - 7:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced the appointment of Thomas Forest Farb-Horch and Agnieszka
Winkler to its Board of Directors, effective October 7, 2021, each
with a three-year term ending concurrently with the Company’s 2024
annual stockholders’ meeting.
Thomas Forest Farb-Horch has over three decades of experience as
an investor in and senior executive of numerous life science and
information technology companies both in the U.S. and
internationally. Mr. Farb has served as the Chief Executive
Officer, President, co-founder and director of Thrive Bioscience,
Inc. since May 2014. He has also served as President, Chief
Operating Officer and in other C-level positions at several other
companies, including Interneuron Pharmaceuticals (NASDAQ), Indevus
Pharmaceuticals (NASDAQ), and Cytyc (NASDAQ). Mr. Farb currently
serves on the boards of directors of North Shore InnoVentures and
AutoImmunity Biologic Solutions, and is a member of the scientific
advisory board of Emervax. Mr. Farb previously served on the boards
of directors of Fair Isaac (NYSE:FICO), Redwood Trust (NYSE:RWT),
HNC Software (NASDAQ), Retek Systems (NASDAQ) and Symon
Communications (NASDAQ). Mr. Farb earned a B.A. in sociology from
Harvard University.
Agnieszka Winkler has extensive professional and board
experience with start-up, mid-cap and Fortune 500 companies. Ms.
Winkler currently serves on the board of directors of Virco
(NASDAQ:VIRC) and the board of trustees of each of Santa Clara
University and the African Diaspora Network. She also serves as
Chair of the board of directors of the Jesuit School of Theology
and as President of the board of Catholic Charities of Santa Clara
County. Ms. Winkler has previously served on numerous public
company boards such as SuperCuts (NASDAQ), Reno Air (NASDAQ), The
Cheesecake Factory (NASDAQ:CAKE), and Inter-Tel (NASDAQ), as well
as private company boards including Ascension, a $22B healthcare
system, Ascension Network and IPLocks. She was the founder and
former Chair and Chief Executive Officer of TeamToolz, a software
company, and Winkler Advertising, both of which were acquired. Ms.
Winkler earned a B.A. in history from Holy Names University, an
M.A. in history from San Jose State University, and an M.B.A. from
Santa Clara University.
Navidea Chief Executive Officer Jed Latkin said, “Navidea is
pleased to add two highly respected and exceptionally talented
individuals to its Board of Directors. Their combined experience
will help guide the Company through its next phases of growth and
development.”
Navidea Chair of the Board Alexander L. Cappello said, “I am
proud to join Jed Latkin in welcoming seasoned directors of such
high caliber as Thomas Farb and Agnieszka Winkler to the Navidea
Board of Directors. Their combined management experience as CEOs,
operators, public company managers, all aspects of leadership and
every possible committee brings a wealth of maturity, relationships
and experience to Navidea.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211014005277/en/
Navidea Biopharmaceuticals, Inc. Jed Latkin Chief Executive
Officer 614-973-7490 jlatkin@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024